MX2023004085A - Metodos para el tratamiento del cáncer. - Google Patents
Metodos para el tratamiento del cáncer.Info
- Publication number
- MX2023004085A MX2023004085A MX2023004085A MX2023004085A MX2023004085A MX 2023004085 A MX2023004085 A MX 2023004085A MX 2023004085 A MX2023004085 A MX 2023004085A MX 2023004085 A MX2023004085 A MX 2023004085A MX 2023004085 A MX2023004085 A MX 2023004085A
- Authority
- MX
- Mexico
- Prior art keywords
- egfr
- her2
- cancer
- treatment
- disorder
- Prior art date
Links
- 108060006698 EGF receptor Proteins 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 102000001301 EGF receptor Human genes 0.000 abstract 2
- 150000005829 chemical entities Chemical class 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 2
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 239000000890 drug combination Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Esta divulgación proporciona entidades químicas (p.ej., un compuesto o una sal farmacéuticamente aceptable y/o hidrato y/o cocristal y/o combinación de fármacos del compuesto) que inhiben el receptor del factor de crecimiento epidérmico (EGFR, ERBB1) y/o el receptor 2 del factor de crecimiento epidérmico (HER2, ERBB2). Estas entidades químicas son útiles, por ejemplo, para tratar una afección, enfermedad o trastorno en el cual el aumento (por ejemplo, excesivo) de la activación de EGFR y/o HER2 contribuye a la patología y/o los síntomas y/o la progresión de la afección, enfermedad o trastorno (por ejemplo, cáncer) en un sujeto (por ejemplo, un ser humano). Esta divulgación también proporciona composiciones que las contienen, así como métodos para usarlas y prepararlas.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063089965P | 2020-10-09 | 2020-10-09 | |
| US202163151468P | 2021-02-19 | 2021-02-19 | |
| PCT/US2021/054191 WO2022076831A2 (en) | 2020-10-09 | 2021-10-08 | Methods for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004085A true MX2023004085A (es) | 2023-06-29 |
Family
ID=78516928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004085A MX2023004085A (es) | 2020-10-09 | 2021-10-08 | Metodos para el tratamiento del cáncer. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240101576A1 (es) |
| EP (1) | EP4225445A2 (es) |
| JP (1) | JP2023548657A (es) |
| KR (1) | KR20230107419A (es) |
| AU (1) | AU2021358596A1 (es) |
| BR (1) | BR112023006531A2 (es) |
| CA (1) | CA3198202A1 (es) |
| CL (1) | CL2023001012A1 (es) |
| IL (1) | IL301929A (es) |
| MX (1) | MX2023004085A (es) |
| TW (1) | TW202227063A (es) |
| WO (1) | WO2022076831A2 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115819418B (zh) * | 2023-02-14 | 2023-04-28 | 山东绿叶制药有限公司 | Plk1激酶抑制剂及其制备方法和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6906194B2 (en) | 2003-10-08 | 2005-06-14 | Massachusetts Instititue Of Technology | Fluorescence assay for kinase activity |
| US7964729B2 (en) | 2006-08-28 | 2011-06-21 | Massachusetts Institute Of Technology | Sox-based kinase sensor |
| JP5825932B2 (ja) | 2011-08-26 | 2015-12-02 | キヤノン株式会社 | 撮像装置及びその制御方法、プログラム、及び記録媒体 |
| EP2794596B1 (en) | 2011-12-21 | 2017-05-31 | Bayer Intellectual Property GmbH | Substituted benzylpyrazoles |
| US20150141372A1 (en) | 2012-05-11 | 2015-05-21 | Bayer Pharma Aktiengesellschaft | Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer |
| US20160046610A1 (en) | 2013-03-21 | 2016-02-18 | Bayer Pharma Aktiengesellschaft | 3-heteroaryl substituted indazoles |
| EP2976335A1 (en) | 2013-03-21 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted indazoles |
| CN105452236A (zh) | 2013-06-21 | 2016-03-30 | 拜耳制药股份公司 | 取代的苄基吡唑 |
| US9745285B2 (en) | 2013-06-21 | 2017-08-29 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| JP2016522232A (ja) | 2013-06-21 | 2016-07-28 | バイエル ファーマ アクチエンゲゼルシャフト | ヘテロアリール置換されたピラゾール類 |
| JP2016525076A (ja) | 2013-06-21 | 2016-08-22 | バイエル ファーマ アクチエンゲゼルシャフト | 置換されたベンジルピラゾール類 |
| JP2016536311A (ja) | 2013-10-30 | 2016-11-24 | バイエル ファーマ アクチエンゲゼルシャフト | ヘテロアリール置換ピラゾール類 |
| EP3143015B1 (en) | 2014-05-13 | 2019-02-20 | ARIAD Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| AR100886A1 (es) | 2014-06-17 | 2016-11-09 | Bayer Pharma AG | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas |
| WO2016202755A1 (en) | 2015-06-17 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones |
| WO2017021348A1 (en) | 2015-08-05 | 2017-02-09 | Bayer Pharma Aktiengesellschaft | 1h-pyrrol-3-amines |
| EP3345907B1 (en) | 2015-09-01 | 2020-04-22 | Taiho Pharmaceutical Co., Ltd. | Pyrazolo[3,4-d]pyrimidine compounds or salts thereof |
| EP3700904B1 (en) * | 2017-10-24 | 2023-07-19 | Bayer AG | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
| BR112020017184A2 (pt) | 2018-02-23 | 2020-12-22 | The Regents Of The University Of Michigan | Disruptores de dímero egfr e uso dos mesmos |
| AU2019287750A1 (en) | 2018-06-14 | 2020-10-15 | Dana-Farber Cancer Institute, Inc. | Cyano quinoline amide compounds as HER2 inhibitors and methods of use |
| US20210346395A1 (en) | 2018-06-21 | 2021-11-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of egfr and methods of use thereof |
| WO2020161257A1 (en) * | 2019-02-07 | 2020-08-13 | Bayer Aktiengesellschaft | 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors |
-
2021
- 2021-10-08 BR BR112023006531A patent/BR112023006531A2/pt unknown
- 2021-10-08 KR KR1020237015734A patent/KR20230107419A/ko unknown
- 2021-10-08 IL IL301929A patent/IL301929A/en unknown
- 2021-10-08 AU AU2021358596A patent/AU2021358596A1/en active Pending
- 2021-10-08 JP JP2023521702A patent/JP2023548657A/ja active Pending
- 2021-10-08 CA CA3198202A patent/CA3198202A1/en active Pending
- 2021-10-08 US US18/030,211 patent/US20240101576A1/en active Pending
- 2021-10-08 EP EP21802493.3A patent/EP4225445A2/en active Pending
- 2021-10-08 MX MX2023004085A patent/MX2023004085A/es unknown
- 2021-10-08 TW TW110137651A patent/TW202227063A/zh unknown
- 2021-10-08 WO PCT/US2021/054191 patent/WO2022076831A2/en active Application Filing
-
2023
- 2023-04-06 CL CL2023001012A patent/CL2023001012A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL301929A (en) | 2023-06-01 |
| WO2022076831A3 (en) | 2022-07-07 |
| KR20230107419A (ko) | 2023-07-14 |
| BR112023006531A2 (pt) | 2023-10-03 |
| WO2022076831A2 (en) | 2022-04-14 |
| TW202227063A (zh) | 2022-07-16 |
| US20240101576A1 (en) | 2024-03-28 |
| JP2023548657A (ja) | 2023-11-20 |
| AU2021358596A1 (en) | 2023-05-25 |
| CL2023001012A1 (es) | 2023-12-22 |
| CA3198202A1 (en) | 2022-04-14 |
| EP4225445A2 (en) | 2023-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023003362A (es) | Derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer. | |
| WO2020150417A3 (en) | Compounds and compositions for treating conditions associated with sting activity | |
| ES2436225T3 (es) | Inhibidores TRPA1 para tratamiento del dolor | |
| AU2016281620B2 (en) | Compositions and methods for inhibiting arginase activity | |
| MX2021015605A (es) | Compuestos 2,3-dihidroquinazolin como inhibidores nav1.8. | |
| CN107613983B (zh) | 抗肿瘤剂的副作用减轻剂 | |
| CR20220230A (es) | Inhibidores de pequeñas moléculas de mutante g12c de kras | |
| JP2019014758A5 (es) | ||
| PH12020552004A1 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| MY145634A (en) | Pyrrolotriazine compounds as kinase inhibitors | |
| MA38380A1 (fr) | Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr) | |
| WO2008094909A3 (en) | Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions | |
| RS20050441A (en) | C-6 modified indazolylpyrroltriazines | |
| CL2023001012A1 (es) | Métodos para el tratamiento del cáncer | |
| MXPA04004492A (es) | Indazolilpirrolotriazinas c-5 modificadas. | |
| EP1773791A4 (en) | PYRROLOTRIAZINVERBINDUNGEN | |
| CR20230185A (es) | Compuestos y su uso en el tratamiento del cáncer | |
| WO2005065266A8 (en) | Di-substituted pyrrolotriazine compounds | |
| RU2013148817A (ru) | Комбинации соединений-ингибиторов акт и мек и способы их применения | |
| EA200870454A1 (ru) | Способ ингибирования c-kit киназы | |
| CA3110658A1 (en) | Compounds, compositions and methods for treating or preventing her-driven cancers | |
| HUP0303466A2 (hu) | Eljárás és adagolási forma tumorok tegafur, uracil, folinsav, paclitaxel és carboplatin beadásával való kezelésére | |
| BR112021022216A2 (pt) | Ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxílico para uso em pacientes com câncer de mama metastático ou avançado | |
| MX2020002429A (es) | Compuestos para reducir la viscosidad de las formulaciones biologicas. | |
| WO2005058245A3 (en) | Synthetic process |